Company news

Jiangsu Recbio Technology Co., Ltd. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 October 2026

November 1, 2026

Voluntary announcement receipt of phase iii clinical trial summary report for novel adjuvanted recombinant shingles vaccine REC610

October 29, 2026

Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 September 2026

October 2, 2026

2026 Interim Report

September 23, 2026

Jiangsu Recbio Technology Says New Drug Application For REC610 Shingles Vaccine Accepted By NMPA

December 29, 2025

Jiangsu Recbio Technology Says Liu Yong Resigned As Chair

December 23, 2025

Jiangsu Recbio Technology Says Li Bu Resigned As Executive Director

December 1, 2025

Decks